This site is intended for healthcare professionals
Micrograph of ovary tissue rendered in blues
  • Home
  • /
  • News
  • /
  • 2026
  • /
  • 11
  • /
  • Personalizing advanced prostate cancer care

Personalizing advanced prostate cancer care

Last updated: 20th Nov 2026
Published: 20th Nov 2026
Author: Litha Mfiki

Personalizing advanced prostate cancer treatment requires integrating disease burden, biomarkers, treatment sequencing, toxicity, and patient preferences

The increased availability of diagnostic and therapeutic tools in advanced prostate cancer has transformed survival, but has it made the right treatment harder to choose? The management of advanced prostate cancer has evolved rapidly with:1-4

  • Androgen receptor pathway inhibitor (ARPI)–based doublets
  • Docetaxel–containing triplets
  • Biomarker–directed therapies
  • Prostate-specific membrane antigen (PSMA)–based imaging

This expanding treatment landscape presents three key challenges for clinicians:5-7

  1. Translating expanding trial data into individualized strategies
  2. Sequencing therapies across the metastatic hormone-sensitive prostate cancer (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC) continuum
  3. Addressing unmet needs in the management of prostate cancer

 

What factors should guide individualized treatment selection in advanced prostate cancer?

Individualized treatment selection in advanced prostate cancer should consider the whole patient rather than follow a uniform approach. Key considerations include:8,9

  • Disease volume and metastatic burden
  • Prognosis and comorbidity profile
  • Toxicity risk
  • Biomarker status
  • Patient preferences

Network meta-analyses consistently favor intensified strategies but highlight uncertainty around the optimal regimen for individual populations.5-7

 

Which biomarkers and imaging tools inform treatment decisions in advanced prostate cancer?

Biomarkers and imaging tools can inform treatment selection and monitoring in advanced prostate cancer as precision medicine becomes increasingly central to care. Relevant tools include:4,10,11

  • Homologous recombination repair (HRR) testing
  • Phosphatase and tensin homolog (PTEN) assessment
  • Genomic profiling
  • PSMA imaging
  • Circulating tumor cell (CTC) assessment

Variability persists in testing practices and in interpreting and integrating results into routine workflows.10

 

How should therapies be sequenced across the mHSPC–mCRPC continuum?

There is currently no established optimal sequence of therapies across the mHSPC–mCRPC continuum10,11. As ARPIs, chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibitors, radioligand therapies, and targeted agents move into earlier disease settings, treatment pathways are becoming increasingly complex.3,10,11 Prospective evidence to guide subsequent treatment after these intensified approaches remains limited.10,11

 

How should emerging evidence from network meta-analyses and real-world data be interpreted in prostate cancer?

Emerging evidence, such as network meta-analyses and real-world data, should be interpreted by assessing study quality, recognizing limitations, and judging how applicable findings are to individuals with prostate cancer before incorporating them into care.5,7,12,13 As the evidence base extends beyond randomized controlled trials, each source type calls for a specific lens:5,7,12,13

  • Network meta-analyses: Useful for comparing competing treatment strategies where direct head-to-head studies are lacking, provided their comparative assumptions are scrutinized
  • Real-world evidence (RWE): Offers insight into treatment effectiveness in broader, more representative patient populations than trial cohorts

Because these methodologies increasingly influence treatment recommendations, confident critical appraisal is essential to apply them appropriately to patient care.5,7,12,13

 

How can quality of life and patient-reported outcomes inform prostate cancer treatment planning?

Quality of life (QoL) and patient-reported outcomes (PROs) can be integrated into prostate cancer treatment planning by embedding PROs, shared decision-making frameworks, and survivorship planning directly into treatment selection and monitoring.14,15 Practical steps include:14-18

  • Assessing fatigue, cognitive function, physical functioning, and the burden of prostate cancer treatment, which significantly influence satisfaction and adherence
  • Factoring in demonstrated preferences for therapies with lower perceived fatigue and fewer adverse effects
  • Incorporating shared decision-making frameworks to align therapy with patient goals
  • Embedding survivorship planning across the disease continuum

This addresses the inconsistent incorporation of QoL, cognitive outcomes, PROs, and survivorship discussions into routine care.14,15

 

Key takeaways

  • Individualized treatment selection should reflect the whole patient (disease volume, metastatic burden, prognosis, comorbidity profile, toxicity risk, biomarker status, and patient preference) rather than a uniform approach8,9
  • Precision medicine tools, including HRR testing, PTEN assessment, genomic profiling, PSMA imaging, and CTC assessment, are increasingly central to care, yet variability persists in testing and interpretation4,10,11
  • Sequencing across the mHSPC–mCRPC continuum remains uncertain as therapies move earlier, with little prospective data to guide pathways after intensified regimens10,11
  • Emerging evidence such as network meta-analyses and real-world data increasingly informs decisions, making critical appraisal of study quality and limitations essential before application5,7
  • QoL and patient-reported outcomes meaningfully influence satisfaction and adherence but remain inconsistently incorporated into treatment planning16-18

 

References

  1. Armstrong, 2022. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. https://www.doi.org/10.1200/JCO.22.00193
  2. Chowdhury, 2023. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. https://www.doi.org/10.1016/j.annonc.2023.02.009
  3. Smith, 2022. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. https://www.doi.org/10.1056/nejmoa2119115
  4. Hofman, 2020. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. https://www.doi.org/10.1016/s0140-6736(20)30314-7
  5. Menges, 2022. Treatments for metastatic hormone-sensitive prostate cancer: Systematic review, network meta-analysis, and benefit-harm assessment. https://www.doi.org/10.1016/j.euo.2022.04.007
  6. Mori, 2022. Systemic therapies for metastatic hormone‐sensitive prostate cancer: Network meta‐analysis. https://www.doi.org/10.1111/bju.15507
  7. Riaz, 2023. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: A living systematic review and network meta-analysis. https://www.doi.org/10.1001/jamaoncol.2022.7762
  8. Matsukawa, 2024. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review, meta-analysis, and network meta-analysis. https://www.doi.org/10.1007/s10147-024-02485-4
  9. Vale, 2023. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: A systematic review and meta-analysis of individual participant data from randomised trials. https://www.doi.org/10.1016/S1470-2045(23)00230-9
  10. Gillessen, 2023. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. https://www.doi.org/10.1016/j.ejca.2023.02.018
  11. Hoeh, 2025. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: An updated network meta-analysis including ARANOTE data. https://www.doi.org/10.1016/j.euf.2024.11.004
  12. Mishra-Kalyani, 2022. External control arms in oncology: Current use and future directions. https://www.doi.org/10.1016/j.annonc.2021.12.015
  13. Kang, 2024. Artificial intelligence across oncology specialties: Current applications and emerging tools. https://www.doi.org/10.1136/bmjonc-2023-000134
  14. Russell, 2024. Survivorship data in prostate cancer: Where are we and where do we need to be? https://www.doi.org/10.1016/j.euros.2023.11.004
  15. Singhal, 2022. Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. https://www.doi.org/10.1038/s41585-022-00575-4
  16. Ng, 2024. Patient preference of apalutamide versus enzalutamide for recurrent or metastatic hormone-sensitive prostate cancer: An open-label, randomized, crossover trial. https://www.doi.org/10.1016/j.euo.2024.04.001
  17. Boué, 2025. Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer. https://www.doi.org/10.1038/s43856-025-01302-x
  18. Cowan, 2024. Treatment-related cognitive impairment in patients with prostate cancer: Patients' real-world insights for optimizing outcomes. https://www.doi.org/10.1007/s12325-023-02721-9
  19. Bell, 2022. Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. https://www.doi.org/10.1016/j.ccell.2021.12.001

Developed by EPG Health for Medthority, independently of any sponsor.

Podcast: Expert exchanges – HRR in mPC

How do HRR mutations transform mPC treatment strategies? From scientific foundations to patient experiences, Alicia Morgans and expert guests deliver the clinical insights you need.

LISTEN NOW

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.